Key Highlights

  • NuCana plc (NASDAQ:NCNA) rose 8.65% to USD 1.13 in the pre-market snapshot of Tuesday, October 27, 2026 with no dated announcement. Cash of GBP 19.5 million funds planned operations into 2029, ahead of final NUC-7738 melanoma data.
  • Citius Oncology (NASDAQ:CTOR) rose 6.63% to USD 0.6352. Nine-month revenue from its LYMPHIR launch was USD 7.1 million against a USD 41.1 million net loss, and cash of USD 16.6 million followed the start of a USD 25.0 million term loan.
  • Tempest Therapeutics (NASDAQ:TPST) rose 5.84% to USD 0.5400, with cash of USD 0.8 million at June 30, 2026 against a quarterly net loss of USD 5.2 million, so financing terms may outweigh its 2026 milestones.
  • Aptevo Therapeutics (NASDAQ:APVO) fell 6.35% to USD 1.40. Cash was USD 9.8 million at June 30, 2026, and a placement of about USD 4.5 million gross left a dilution overhang despite a 93% clinical benefit rate in a small cohort.

NuCana (NASDAQ:NCNA): the longest runway ahead of a binary readout

NuCana plc (NASDAQ:NCNA), an Edinburgh-based clinical-stage oncology company, traded 8.65% higher at USD 1.13 in the pre-market snapshot. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move, so the advance appears consistent with positioning ahead of the NUC-7738 readout and with thin pre-market liquidity. Both explanations are inferences, and prices can change before the open at 9:30 a.m. ET. In the release of Thursday, August 13, 2026, NuCana reported a net loss of GBP 3.1 million for the quarter ended June 30, 2026, against GBP 24.1 million a year earlier, with no revenue. A warrant fair-value finance expense of GBP 12.6 million in the first half of 2025 did not recur. Cash and cash equivalents were GBP 19.5 million, which the company stated funds planned operations into 2029.

Runway is therefore the least pressing variable here, and the clinical result becomes the driver. The bull reading is activity in PD-1 inhibitor-resistant melanoma, which would support a request for guidance from the US Food and Drug Administration. The bear reading is a weak result for a company without revenue and dependent on one lead asset. The share price sits near the USD 1.00 level that Nasdaq uses as a minimum bid threshold.

Citius Oncology (NASDAQ:CTOR): launch revenue against cash burn

Citius Oncology (NASDAQ:CTOR), a late-stage oncology company that markets LYMPHIR for cutaneous T-cell lymphoma, a cancer of the skin-homing white blood cells, traded 6.63% higher at USD 0.6352. No company-specific announcement dated on or just before the session accompanied the move, and the latest related release, of Monday, October 12, 2026, announced investor conference presentations. The rise appears consistent with thin liquidity in a sub-USD 1.00 stock, which is an inference.

The release of Friday, August 14, 2026 reported fiscal third quarter revenue of USD 1.5 million. Vial orders rose 31% sequentially to 926 from 708, and 44 institutions had ordered since launch. The nine-month net loss of USD 41.1 million includes a one-time USD 19.7 million charge for a cancelled manufacturing contract. Cash of USD 16.6 million included USD 9.7 million from warrant exercises and USD 10.0 million from the first tranche of the term loan. The driver is launch pace against a quarterly net loss of USD 8.9 million. A nine-month gross margin of about 77%, by simple arithmetic on USD 5.5 million and USD 7.1 million, supports the bull reading. Repayment obligations under the term loan and further warrant issuance support the bear reading, as does a price below the USD 1.00 Nasdaq benchmark.

Tempest Therapeutics (NASDAQ:TPST): a near-empty balance sheet

Tempest Therapeutics (NASDAQ:TPST), a clinical-stage oncology company developing small molecules and an antibody-based asset, traded 5.84% higher at USD 0.5400. No company-specific announcement dated on or just before the session accompanied the move, which appears consistent with thin pre-market liquidity, where few orders can shift the quote. The most recent company communication is the release of Thursday, August 13, 2026, which covered the quarter ended June 30, 2026. The shares trade below USD 1.00, the level relevant to the Nasdaq minimum bid price requirement.

That release reported a net loss of USD 5.2 million, or USD 0.34 per share, for the quarter ended June 30, 2026, against USD 7.9 million a year earlier. Research and development expense fell to USD 1.8 million from USD 3.9 million. Cash was USD 0.8 million, against USD 7.7 million at December 31, 2025, and the year-end report of Monday, March 30, 2026 cited going concern risk and a need for additional capital. The balance sheet, not the pipeline, is the main influence on the price. The bull reading rests on a potentially registrational study of TPST-2003 in relapsed or refractory multiple myeloma and first dosing of TPST-4003 in China in the fourth quarter of 2026. The bear reading is dilution from any equity raise.

Aptevo Therapeutics (NASDAQ:APVO): promising data and a dilution overhang

Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage company developing multispecific antibodies for blood cancers and solid tumours, traded 6.35% lower at USD 1.40. No company-specific announcement dated on or just before the session accompanied the move, and the latest release, of Wednesday, October 14, 2026, announced a platform presentation at the SITC Annual Meeting from Wednesday, November 4, 2026. The decline appears consistent with thin liquidity and financing overhang, which is an inference.

In its update of Friday, August 14, 2026, the company reported cash and equivalents of USD 9.8 million at June 30, 2026, with USD 0.6 million raised through a standby equity purchase facility. The warrant inducement and private placement of Wednesday, August 12, 2026 raised about USD 4.5 million gross. On Thursday, September 3, 2026, mipletamig showed a 93% clinical benefit rate, 13 of 14 evaluable patients, in frontline TP53-mutated acute myeloid leukaemia. Favourable data and new shares pull in opposite directions. The bull reading is a regulatory interaction planned for the first half of 2027. The bear reading is small patient numbers and up to 4,308,540 common warrant shares that require stockholder approval, which add to potential dilution.

Where Things Stand

The answer is that cash runway can decide how each oncology name trades, but through different channels. NuCana (NASDAQ:NCNA) has funding into 2029, so its melanoma data dominate. Citius Oncology (NASDAQ:CTOR) depends on LYMPHIR orders outrunning a quarterly loss of USD 8.9 million. Tempest Therapeutics (NASDAQ:TPST) and Aptevo Therapeutics (NASDAQ:APVO) are exposed to the terms of future equity, from USD 0.8 million and USD 9.8 million of cash respectively.

The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026, the SITC Annual Meeting from Wednesday, November 4, 2026, fourth-quarter 2026 dosing of TPST-4003 and final NUC-7738 data later in 2026. Pre-market prices are snapshots and can change, and this is not investment advice.